Proteomic Serum Biomarkers and Their Potential Application in Cancer Screening Programs

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2010 Dec 15

PMID 21151433

Citations 15

Authors

Anouck Huijbers

Berit Velstra

Tim J A Dekker

Wilma E Mesker

Yuri E M van der Burgt

Bart J Mertens

Andre M Deelder

Rob A E M Tollenaar

Affiliations

Soon will be listed here.

Abstract

Early diagnosis of cancer is of pivotal importance to reduce disease-related mortality. There is great need for non-invasive screening methods, yet current screening protocols have limited sensitivity and specificity. The use of serum biomarkers to discriminate cancer patients from healthy persons might be a tool to improve screening programs. Mass spectrometry based proteomics is widely applied as a technology for mapping and identifying peptides and proteins in body fluids. One commonly used approach in proteomics is peptide and protein profiling. Here, we present an overview of profiling methods that have the potential for implementation in a clinical setting and in national screening programs.

Citing Articles

Biological Basis of Breast Cancer-Related Disparities in Precision Oncology Era.

Neagu A, Bruno P, Johnson K, Ballestas G, Darie C Int J Mol Sci. 2024; 25(7).

PMID: 38612922 PMC: 11012526. DOI: 10.3390/ijms25074113.

Small Non-Coding RNAs and Their Role in Locoregional Metastasis and Outcomes in Early-Stage Breast Cancer Patients.

Escuin D, Bell O, Garcia-Valdecasas B, Clos M, Larranaga I, Lopez-Vilaro L Int J Mol Sci. 2024; 25(7).

PMID: 38612790 PMC: 11011815. DOI: 10.3390/ijms25073982.

Elucidating the susceptibility to breast cancer: an in-depth proteomic and transcriptomic investigation into novel potential plasma protein biomarkers.

Wang Y, Yi K, Chen B, Zhang B, Jidong G Front Mol Biosci. 2024; 10:1340917.

PMID: 38304232 PMC: 10833003. DOI: 10.3389/fmolb.2023.1340917.

Abilities of Pre-Treatment Inflammation Ratios as Classification or Prediction Models for Patients with Colorectal Cancer.

Ciocan A, A Ciocan R, Al Hajjar N, Gherman C, Bolboaca S Diagnostics (Basel). 2021; 11(3).

PMID: 33801031 PMC: 8003848. DOI: 10.3390/diagnostics11030566.

ITIH4: Effective Serum Marker, Early Warning and Diagnosis, Hepatocellular Carcinoma.

Li X, Li B, Li B, Guo T, Sun Z, Li X Pathol Oncol Res. 2017; 24(3):663-670.

PMID: 28828637 DOI: 10.1007/s12253-017-0285-4.

References

Wang Q, Shen J, Li Z, Jie J, Wang W, Wang J . Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer. 2009; 9:287. PMC: 2743709. DOI: 10.1186/1471-2407-9-287. View

Liotta L, Petricoin E . Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest. 2006; 116(1):26-30. PMC: 1323272. DOI: 10.1172/JCI27467. View

Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B . The case for early detection. Nat Rev Cancer. 2003; 3(4):243-52. DOI: 10.1038/nrc1041. View

Roder D, Houssami N, Farshid G, Gill G, Luke C, Downey P . Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res Treat. 2008; 108(3):409-16. DOI: 10.1007/s10549-007-9609-5. View

Villanueva J, Philip J, Entenberg D, Chaparro C, Tanwar M, Holland E . Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem. 2004; 76(6):1560-70. DOI: 10.1021/ac0352171. View

Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D . A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer. 2003; 4(3):203-9. DOI: 10.3816/cbc.2003.n.026. View

Habermann J, Roblick U, Luke B, Prieto D, Finlay W, Podust V . Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology. 2006; 131(4):1020-9. PMC: 2532535. DOI: 10.1053/j.gastro.2006.07.011. View

Mertens B, de Noo M, Tollenaar R, Deelder A . Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm. J Comput Biol. 2006; 13(9):1591-605. DOI: 10.1089/cmb.2006.13.1591. View

Levin B, Lieberman D, McFarland B, Andrews K, Brooks D, Bond J . Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008; 134(5):1570-95. DOI: 10.1053/j.gastro.2008.02.002. View

10.

Li J, Zhang Z, Rosenzweig J, Wang Y, Chan D . Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002; 48(8):1296-304. View

11.

Fan Y, Wang J, Yang Y, Liu Q, Fan Y, Yu J . Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol. 2010; 136(8):1243-54. DOI: 10.1007/s00432-010-0775-1. View

12.

. A gene-centric human proteome project: HUPO--the Human Proteome organization. Mol Cell Proteomics. 2010; 9(2):427-9. PMC: 2830851. DOI: 10.1074/mcp.H900001-MCP200. View

13.

Zhao G, Gao C, Song G, Li D, Wang X . [Identification of colorectal cancer using proteomic patterns in serum]. Ai Zheng. 2004; 23(6):614-8. View

14.

Anderson N, Anderson N . The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1(11):845-67. DOI: 10.1074/mcp.r200007-mcp200. View

15.

Mauri P, Scigelova M . Multidimensional protein identification technology for clinical proteomic analysis. Clin Chem Lab Med. 2009; 47(6):636-46. DOI: 10.1515/CCLM.2009.165. View

16.

Gotzsche P, Nielsen M . Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2009; (4):CD001877. DOI: 10.1002/14651858.CD001877.pub3. View

17.

Carr S, Aebersold R, Baldwin M, Burlingame A, Clauser K, Nesvizhskii A . The need for guidelines in publication of peptide and protein identification data: Working Group on Publication Guidelines for Peptide and Protein Identification Data. Mol Cell Proteomics. 2004; 3(6):531-3. DOI: 10.1074/mcp.T400006-MCP200. View

18.

Villanueva J, Shaffer D, Philip J, Chaparro C, Erdjument-Bromage H, Olshen A . Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006; 116(1):271-84. PMC: 1323259. DOI: 10.1172/JCI26022. View

19.

Villanueva J, Philip J, Chaparro C, Li Y, Toledo-Crow R, DeNoyer L . Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res. 2005; 4(4):1060-72. PMC: 1852495. DOI: 10.1021/pr050034b. View

20.

Yu J, Chen Y, Zheng S . An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J Gastroenterol. 2004; 10(21):3127-31. PMC: 4611255. DOI: 10.3748/wjg.v10.i21.3127. View